JP2014513141A5 - - Google Patents

Download PDF

Info

Publication number
JP2014513141A5
JP2014513141A5 JP2014509519A JP2014509519A JP2014513141A5 JP 2014513141 A5 JP2014513141 A5 JP 2014513141A5 JP 2014509519 A JP2014509519 A JP 2014509519A JP 2014509519 A JP2014509519 A JP 2014509519A JP 2014513141 A5 JP2014513141 A5 JP 2014513141A5
Authority
JP
Japan
Prior art keywords
composition
hydrogen
subject
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014509519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513141A (ja
JP6122420B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/036841 external-priority patent/WO2012154695A2/en
Publication of JP2014513141A publication Critical patent/JP2014513141A/ja
Publication of JP2014513141A5 publication Critical patent/JP2014513141A5/ja
Application granted granted Critical
Publication of JP6122420B2 publication Critical patent/JP6122420B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014509519A 2011-05-06 2012-05-07 多発性嚢胞疾患の治療 Active JP6122420B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161483630P 2011-05-06 2011-05-06
US61/483,630 2011-05-06
PCT/US2012/036841 WO2012154695A2 (en) 2011-05-06 2012-05-07 Treatment of polycystic disease

Publications (3)

Publication Number Publication Date
JP2014513141A JP2014513141A (ja) 2014-05-29
JP2014513141A5 true JP2014513141A5 (enExample) 2015-09-10
JP6122420B2 JP6122420B2 (ja) 2017-04-26

Family

ID=47139933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014509519A Active JP6122420B2 (ja) 2011-05-06 2012-05-07 多発性嚢胞疾患の治療

Country Status (6)

Country Link
US (1) US20140066462A1 (enExample)
EP (1) EP2704723A4 (enExample)
JP (1) JP6122420B2 (enExample)
CN (1) CN103796655A (enExample)
CA (1) CA2835197A1 (enExample)
WO (1) WO2012154695A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
EP3193902A4 (en) 2014-09-11 2018-03-28 The Regents of The University of California mTORC1 INHIBITORS
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
MX389001B (es) * 2015-10-23 2025-03-20 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
US10623555B2 (en) 2016-09-27 2020-04-14 Hartford Fire Insurance Company Controlling a graphical user interface for workflow
FR3075795A1 (fr) * 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075794A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
PL3788049T3 (pl) 2018-05-01 2023-06-19 Revolution Medicines, Inc. Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
EP4531859A4 (en) 2022-05-25 2026-05-27 Revolution Medicines Inc CANCER TREATMENT METHODS USING AN MTOR INHIBITOR

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
MX2011000216A (es) * 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
UA111579C2 (uk) * 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
JP6047149B2 (ja) * 2011-05-04 2016-12-21 インテリカイン, エルエルシー 併用の医薬組成物およびその使用

Similar Documents

Publication Publication Date Title
JP2013542247A5 (enExample)
JP2014507477A5 (enExample)
JP2013542261A5 (enExample)
JP2013510120A5 (enExample)
JP2011502174A5 (enExample)
JP2012512907A5 (enExample)
JP2014500861A5 (enExample)
JP2010515715A5 (enExample)
JP2013537905A5 (enExample)
JP2008195730A5 (enExample)
JP2017008088A5 (enExample)
JP2012092110A5 (enExample)
JP2014510729A5 (enExample)
JP2013518056A5 (enExample)
JP2008533007A5 (enExample)
JP2015502974A5 (enExample)
RU2013121788A (ru) Ингибиторы репликации вич
JP2011504903A5 (enExample)
JP2012532883A5 (enExample)
JP2015509075A5 (enExample)
JP2016510326A5 (enExample)
JP2016193917A5 (enExample)
RU2010147832A (ru) Диэфирные пролекарства налмефена
JP2013518036A5 (enExample)
JP2012522841A5 (enExample)